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a b s t r a c t
Urine and breast milk represent the main routes of human cytomegalovirus (HCMV) transmission but
the contribution of renal and mammary epithelial cells to viral excretion remains unclear. We observed
that kidney and mammary epithelial cells were permissive to HCMV infection and expressed immediate
early, early and late antigens within 72 h of infection. During the ﬁrst 24 h after infection, high titers of
infectious virus were measured associated to the cells and in culture supernatants, independently of de
novo synthesis of virus progeny. This phenomenon was not observed in HCMV-infected ﬁbroblasts and
suggested the sequestration and the release of HCMV by epithelial cells. This hypothesis was supported
by confocal and electron microscopy analyses. The sequestration and progressive release of HCMV by
kidney and mammary epithelial cells may play an important role in the excretion of the virus in urine
and breast milk and may thereby contribute to HCMV transmission.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Human cytomegalovirus (HCMV) infection is usually asymptomatic
in immune-competent adults. However, HCMV is an important
pathogen in immunocompromised patients with stem cell or solid
organ transplantation, AIDS or cancer. In these patients, HCMV
infection is a signiﬁcant cause of morbidity and mortality, despite
the availability of ﬁve antiviral drugs that are currently licensed for
therapy of HCMV infections. Additionally, HCMV is the leading viral
cause of congenital infection, affecting 1–4% of all live births (Andrei
et al., 2008, 2009; Bale, 2012; Gabrielli et al., 2012; van der Sande et al.,
2007), and antiviral treatment options for congenital HCMV infections
are limited (Jacobson et al., 2006, 2009; Marschall and Stamminger,
2009). Several vaccine candidates are under development but none of
them has yet been licensed for prophylactic vaccination (Bernstein
2011; Dasari et al., 2011; Olejniczak et al., 2011; Pass, 2009a; Pass
et al., 2009b; Saccoccio et al., 2011; Steininger, 2012; Zhong and
Khanna, 2009).
HCMV is transmitted through saliva, urine, breast milk, and
genital secretions (Hamprecht et al., 2008; Staras et al., 2008a).
Following primary HCMV infection in adults, excretion of HCMV
is common in genital secretions, saliva and urine and infection in
early life is associated with prolonged excretion of the virus in urine
(Marchant et al., 2003; Staras et al., 2008a, 2008b). In chronically
infected subjects, viral excretion in genital secretions is common and
excretion in breast milk is common in lactating women (Hamprecht
et al., 2008) and in a mouse model of natural murine CMV infection
of neonates (Wu et al., 2011). Maternal excretion of HCMV in breast
milk and genital secretions was recently shown to be a risk factor for
in utero transmission of the virus (Kaye et al., 2008). The mechanisms
underlying HCMV shedding in body ﬂuids remain poorly understood.
A better understanding of these mechanisms would help in the
design of strategies reducing HCMV transmission.
in vivo, HCMV is able to infect different cell types in several tissues,
including macrophages, endothelial, epithelial, stromal, neuronal and
smooth muscle cells. in vitro, however, full productive infection occurs
mostly in ﬁbroblasts and has also been observed in endothelial cells, in
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fully differentiated myeloid cells, as well as in primary cultures of
hepatocytes and lung epithelial cells (Bain and Sinclair, 2007; Sinzger
et al., 2008; Vanarsdall and Johnson, 2012). Infection of ﬁbroblasts and
endothelial/epithelial cells involves partly different mechanisms.
Fibroblast infection involves viral fusion and the gH/gL/gO complex
of HCMV proteins whereas infection of endothelial and epithelial cells
involves endocytosis and the gH/gL/UL128–131 viral protein complex
(Fouts et al., 2012; Gerna et al., 2008; Lilleri et al., 2012; Macagno et al.,
2010; Schuessler et al., 2012; Sinzger et al., 2008; Straschewski et al.,
2011; Vanarsdall et al., 2008, 2011; Wille et al., 2010).
In order to gain insight into the mechanisms involved in HCMV
excretion in urine and breast milk, we characterized HCMV
infection of clinically relevant primary epithelial cells isolated
from kidney and mammary gland. Our results indicate that human
renal and mammary epithelial cells support productive HCMV
infection and also sequester and release infectious virions inde-
pendently of de novo synthesis of virus progeny.
Results
HCMV replication in primary renal and mammary epithelial cells
To analyze whether HCMV can infect primary renal and
mammary epithelial cells, the kinetics of expression of different
HCMV antigens (Immediate Early and Early antigens) was deter-
mined by ﬂow cytometry and quantitative Real Time-PCR of pp65
DNA was performed to determine viral DNA load. In parallel, a
virus yield assay was performed to quantify the intracellular and
extracellular titers of virus. Fibroblasts were used as a reference for
productive infection. Fig. 1 shows the kinetics of expression of IE
and E antigens and production of pp65 DNA in the three cell types
following infection at a MOI of 0.1 with HCMV TB40/E. At 4 hpi,
less than 1% of HEL cells and epithelial cells expressed IE antigens.
After 24 hpi, about 40% of HEL cells and 10% of epithelial cells
expressed IE antigens whereas at 72 hpi 50% of the HEL cells and
15% of epithelial cells were IE antigen positive. At 72 hpi, 30% of
HEL cells expressed E antigens whereas only 5% and 10% of renal
and mammary epithelial cells were E antigen positive, respec-
tively. The high percentage of infected cells measured by ﬂow
cytometry as compared to the input MOI of 0.1 can be attributed to
the fact that the MOIs were calculated on the basis of a plaque
assay and indicates that a proportion of infected cells do not form
plaques. Of note, ﬂow cytometry was more sensitive than indirect
immuno-ﬂuorescence microscopy and detected about 3- to 5-fold
more infected cells expressing IE or E antigens (data not shown).
Analysis of pp65 DNA showed that TB40/E-infected ﬁbro-
blasts produced about 3.2106 copies at 24 hpi and renal and
mammary epithelial cells expressed 3.7106 and 3.6105 copies,
Fig. 1. HCMV infection of primary epithelial cells and ﬁbroblasts. HEL ﬁbroblasts, human primary renal and mammary epithelial cells were grown to conﬂuence and infected
with HCMV strain TB40/E. Temporal expression of HCMV antigens (IE and E antigens) was measured by ﬂow cytometry at different times post-infection at a MOI of 0.1. Late
pp65 DNA expression was measured by RT-PCR. The ﬁgure shows the means7standard deviation (SD) of three experiments.
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respectively. 3.41011 copies were produced by infected ﬁbro-
blasts 7 days post-infection whereas renal and mammary epithe-
lial cells expressed 1.91010 and 2.8108 copies, respectively
(Fig. 1). Of note, the proportions of IE and E antigen positive
mammary epithelial cells decreased between day 3 and day 7. This
was associated with a higher mortality in epithelial cells as
compared to ﬁbroblast, as determined by light microscopy exam-
ination (data not shown). These results suggest that primary
mammary and renal cells are able to support the full replication
of HCMV and that the virus appears to replicate with a delayed
kinetics in mammary epithelial cells as compared to ﬁbroblasts
and renal epithelial cells.
Analysis of infectious virus titers revealed important differ-
ences between HEL and primary epithelial cells (Fig. 2A–E).
At early stages of viral infection, more infectious progeny viruses
(as determined by plaque assay) were detected in the super-
natants and in cell lysates of primary renal and mammary
epithelial cells than in ﬁbroblasts despite extensive washing to
remove unbound inoculum virus. Up to 24 hpi, no signiﬁcant
amount of virus was measured in HEL cells, either in the super-
natants or associated to the cells. Infectious virus was detected
only at 72 hpi in HEL cells. In contrast, high and stable titers of
infectious virus were measured in epithelial cell supernatants and
intracellular fractions between 4 and 72 hpi. Titers of infectious
virus produced by epithelial cells then increased between 72 h and
7 days post-infection. Viral titers in supernatants and in cell lysates
were about 2 log higher in epithelial cells than in ﬁbroblasts at 4,
8, and 24 hpi when the infection was performed at a MOI of 0.1. At
lower MOI's, lower amounts of virus were measured in epithelial
cells but the titers were still higher than in HEL cells (Fig. 2A–C). A
comparison of virus titers detected in supernatants and associated
to ﬁbroblasts and epithelial cells is shown in Fig. 2D and E. As only
low HCMV IE antigen expression was detected during the ﬁrst
24 hpi, these results suggest that part of the viral inoculum
strongly adhered to epithelial cells and not to ﬁbroblasts and
was released back into culture supernatants as infectious virus.
The proportion of sequestered virus was estimated to be 1–6% of
the inoculum virus considering that the input virus was about
5104 PFU and about 3102–103 PFU were detected in super-
natants or associated to the cells at 24 hpi. As indicated in Fig. 2F,
the amount of virus detected in the supernatants further increased
when the MOI was increased to 0.2 but the amount of cell-
associated virus remained stable, suggesting that the association
of HCMV with epithelial cells can be saturated. In these experi-
ments, the infectivity of the adherent virus was determined in a
ﬁbroblast plaque assay. In order to determine if the adherent viral
particles had a defective capacity to infect epithelial cells, the
expression of IE antigen and the production of infectious particles
were measured following the incubation of supernatants collected
24 hpi with fresh epithelial cells. As shown in Fig. 2G, epithelial cells
were infected with a similar efﬁciency by viral particles contained in
supernatants and by the original virus stock. These data indicate that
the adherence of HCMV particles to epithelial cells was not related to
a defect in their capacity to infect this cell type.
Sequestration of HCMV particles by epithelial cells involves
interactions with heparin sulfates
Experiments were carried out to determine if HCMV seques-
tration by epithelial cells involves interactions with the same
molecules as those involved in virus entry. Virus entry begins
with virion attachment to the ubiquitously expressed heparan
sulfate proteoglycans (HSPGs) at the cell surface (Compton et al.,
1993), followed by engagement of one or more receptor
(s) including the integrin heterodimers α2β1, α6β1, and ανβ3
(Isaacson et al., 2007), the platelet-derived growth factor receptor-α
(Soroceanu et al., 2008), and the epidermal growth factor receptor
(Wang et al., 2003). We ﬁrst examined the effect of dextran sulfate,
which inhibits the binding of HCMV envelope glycoprotein gB to
HSPGs (Compton et al., 1993). Renal and mammary epithelial cells
were infected at a MOI of 0.1 in the presence of different concen-
trations of dextran sulfate and titers of infectious virus were
measured in supernatants and in cell lysates at 24 hpi. As shown
in Fig. 3A and B, dextran sulfate markedly reduced virus titers in a
dose dependent manner, its effects being more pronounced in
mammary compared to renal epithelial cells. We then examined
the effect of heparinase treatment on HCMV sequestration. Pre-
treatment of mammary epithelial cells with heparinase I one hour
before and throughout the experiment reduced the titer of infec-
tious virus in supernatants and in cell lysates (Fig. 3B). Heparinase I
also decreased HCMV sequestration by renal epithelial cells but this
was only apparent for virus titers measured in supernatants.
Together, these results indicate that HCMV sequestration by epithe-
lial cells involves interactions with cellular HSPGs and that the
relative role of these two molecules is different in mammary and
renal cells.
Sequestration of HCMV particles by primary renal and mammary
epithelial cells
In order to gain insight into the nature of the interaction
between adherent HCMV particles and epithelial cells, we studied
the effect of trypsin treatment and low pH wash on the virus titers
detected in supernatants and in cell lysates during the ﬁrst 24 hpi.
Renal and mammary epithelial cells were infected at a MOI of
0.1 for two hours at 37 1C. Cells were then treated with 0.1%
trypsin and seeded in new culture bottles or washed with sodium
citrate buffer before addition of fresh medium. At 24 hpi, titers of
infectious virus were measured with a ﬁbroblast plaque assay.
As shown in Fig. 4A and B, virus titers were not signiﬁcantly
inﬂuenced by trypsin treatment or low pH wash of renal and
mammary epithelial cells. These results indicate that the interac-
tion between sequestered HCMV particles and epithelial cells is
resistant to trypsin and low pH treatment and suggest that viral
particles may be physically protected by epithelial cell structures.
HCMV sequestration by primary epithelial cells does not involve viral
replication or remodeling of the cellular cytoskeleton
The early release of HCMV progeny from infected epithelial
cells suggested no involvement of viral replication. To verify this
point, cells were pre-treated for 30 min with the inhibitors of virus
maturation brefeldin-A (BFA) and tall oil fatty acid (TOFA) (Eggers
et al., 1992; Kregler et al., 2009; Munger et al., 2008). As shown in
Table 1, BFA and TOFA did not inﬂuence the titers of infectious
virus particles measured at 24 hpi in supernatants or in cell
lysates. The concentrations used markedly reduced the virus titers
measured 7 days post-infection (Supplementary Fig. 1). These data
were obtained in ﬁbroblasts because higher virus titers and better
cell survival were obtained with this cell type 7 days post
infection. Similar results were obtained with infected cells treated
with ganciclovir. In addition, protein inhibition by cycloheximide
abrogated immediate early protein expression but did not inﬂu-
ence viral sequestration by renal epithelial cells at 24 hpi
(Supplementary Fig. 2). Together, these results conﬁrmed that
the early detection of infectious virus in the supernatants and
associated to epithelial cells does not require de novo synthesis of
virus progeny. In order to examine the role of the cytoskeleton in
HCMV sequestration, we analyzed the effect of inhibitors of its
three major components, i.e. microﬁlaments, intermediate ﬁla-
ments, and microtubules. Microtubules and microﬁlaments facil-
itate HCMV viral capsid transport towards the nucleus, while the
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vimentin intermediate ﬁlaments may facilitate capsid trafﬁcking
and/or docking to the nuclear envelope (Jones et al., 1986; Miller
and Hertel, 2009). As shown in Table 1, virus titers measured in
supernatants and in cell lysates at 24 hpi were not inﬂuenced by
colchicine, an inhibitor of tubulin polymerization, acrylamide, a
chemical disruptor of the vimentin network, or cytochalasin B, an
Fig. 2. Sequestration of HCMV by primary epithelial cells. HEL ﬁbroblasts (A), human primary mammary (B) and renal (C) epithelial cells were grown to conﬂuence and
infected with HCMV strain TB40/E. Viral titers in culture supernatants (SN) were determined by plaque assay at different times post-infection and at different MOI's. Data are
means of three independent experiments. (D) and (E) Virus yields in culture supernatants (SN) and in cell lysates (intracellular, IC) were measured by plaque assay at 24 hpi
at a MOI of 0.1. (F) Primary renal epithelial cells were infected with the indicated MOI and virus yields in culture supernatants (SN) and in cell lysates (intracellular, IC) were
measured by plaque assay at 24 hpi. (G) Primary renal epithelial cells were infected with the virus contained in the supernatant of previously infected renal epithelial cells or
with the original virus stock and HCMV IE antigens expression was measured by ﬂow cytometry at 7 days post-infection. Data are one representative out of three
experiments (A–C) or means7standard deviation (SD) of three independent experiments (D–G). npo0.05; nnpo0.01.
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inhibitor of the actin ﬁlament network. These results indicate that
HCMV sequestration by epithelial cells is not dependent on the
remodeling of the cellular cytoskeleton.
Confocal and electron microscopy analyses of HCMV-infected
epithelial cells
The results presented above strongly suggested that HCMV
particles are sequestered at the surface of epithelial cells. In order
to further examine this possibility, localization of HCMV envelope
gB was analyzed in epithelial cells and ﬁbroblasts at 24 hpi by
confocal microscopy. As shown in Fig. 5A, HCMV gB was detected
at 24 hpi on the cell surface of non-permeabilized primary
renal and mammary cells but not at the surface of ﬁbroblasts.
In contrast, nuclear staining for HCMV IE antigens was detectable
in most HCMV-infected ﬁbroblasts and in fewer epithelial cells.
These results support the notion that HCMV particles are asso-
ciated with the membrane of infected epithelial cells but not with
that of ﬁbroblasts. To further substantiate this notion, HCMV-
infected epithelial cells and ﬁbroblasts were analyzed by electron
microscopy at 24 hpi. As shown in Fig. 5B, mature enveloped virus
particles were observed beside the plasma membrane of kidney
and mammary epithelial cells. This picture was not observed at
the level of infected ﬁbroblasts (data not shown). Together, the
microscopic analysis is consistent with part of the input virus is
not entering epithelial cells but remaining associated with the
plasma membrane.
HCMV sequestration by epithelial cells is inhibited by anti-HCMV
antibodies and by IFN-γ
Adaptive immunity plays a central role in controlling HCMV
infection and replication in target cells (Isaacson and Compton,
2009). In order to determine its capacity to modulate the amount
of HCMV particles sequestered by epithelial cells, we examined the
effect of anti-HCMV antibodies and of the anti-viral cytokine IFN-
γ. As shown in Fig. 6A and D, treatment of input virus with HCMV
immune serum or a neutralizing anti-gB mAb reduced virus titers
in supernatants and in cell lysates of renal and mammary
epithelial cells. However, immune serum failed to inﬂuence
in situ the amount of sequestered virus when added 2 hpi of both
epithelial cell types (data not shown). Interestingly, pretreatment
with IFN-γ also markedly reduced the amount of sequestered
particles in mammary and renal epithelial cells measured 24 hpi
(Fig. 6C). As expected, neutralizing anti-gB mAb, immune serum
and IFN-γ treatment inhibited virus replication in both cell types,
as measured 7 days post-infection (data not shown). Together,
these results indicate that the amount of HCMV particles
Fig. 3. Sequestration of HCMV particles by epithelial cells involves interactions with heparin sulfates. Renal and mammary epithelial cells were infected at a MOI of 0.1 with
HCMV strain TB40/E. At 24 hpi, virus titers in culture supernatants (SN) and in cell lysates (intracellular, IC) were determined by plaque assay. (A) Cells were infected in the
presence of the indicated concentrations of dextran sulfate. (B) Prior to infection, cells were treated with heparinase I (10 U) at 37 1C for one hour. Data are means7SD of
three independent experiments. ns: not signiﬁcant, npo0.05 and nnpo0.01 as compared to cultures without dextran sulfate or heparinase treatment.
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sequestered by epithelial cells can be modulated by neutralizing
antibodies and by an anti-viral cytokine.
Discussion
Previous studies have demonstrated the presence of HCMV
particles in urine and breast milk and these ﬂuids are recognized
as the main routes of HCMV transmission (Hamele et al., 2010;
Jobe, 2009; Kaye et al., 2008; Rosenthal et al., 2009). This study
shows that HCMV can replicate in primary renal and mammary
epithelial cells, albeit with a different kinetics than in the proto-
type cells (i.e. ﬁbroblasts). It appears therefore that renal and
mammary epithelial cells can be directly involved in HCMV
excretion and transmission. The difference between infection
efﬁciency of epithelial cells and ﬁbroblasts may be attributed to
possible differences in the expression of cell-speciﬁc receptors for
HCMV tethering, docking and entry. These results are consistent
with previous studies showing the ability of renal epithelial cells
to support HCMV replication (Sinzger et al., 2008) and demon-
strate a complete permissiveness of primary mammary epithelial
cells to an efﬁcient and productive HCMV infection with an
endothelial-cell-adapted HCMV strain. In addition, our results
indicate that HCMV can be sequestered and then released by
primary renal and mammary epithelial cells. After thorough
washing of infected epithelial cells, a pool of infectious virus was
detected in culture supernatants and associated to the cells. This
pattern of virus distribution was maintained for at least 24 hpi and
was not observed in human ﬁbroblasts. Considering the life cycle
of HCMV and the kinetics of virus production we observed in
epithelial cells, the infectious virions recovered during the ﬁrst
24 hpi were not the result of de novo virus production but most
likely derived from the viral inoculum. Supporting this notion, the
early detection of infectious virions was not inﬂuenced by inhibi-
tors of HCMV replication. Brefeldin-A inhibits several steps of viral
Fig. 4. HCMV particles sequestered by epithelial cells are resistant to trypsin treatment and low pH wash. Renal and mammary epithelial cells were infected at a MOI of
0.1 with the HCMV strain TB40/E. Two hours post-infection, cells were treated with 0.1% trypsin (A) or washed with citrate buffer (B) before addition of fresh medium.
At 24 hpi, cell-associated virus (intracellular, IC) and virus present in the culture supernatants (SN) were determined by plaque assay. Data are means7SD of three
independent experiments. ns: not signiﬁcant, as compared to cultures without trypsin treatment or low pH wash.
Table 1
Modulation of HCMV sequestration by epithelial cells.
Conditions Renal epithelial cells Mammary epithelial cells
SN IC SN IC
Medium control 2.2670.12n 1.2170.20n 3.0570.27n 2.2970.10n
TOFA 1.9670.48 1.7570.43 2.8770.11 2.6870.17
Brefeldin A 2.2470.34 1.0770.12 3.1370.33 2.1770.16
Ganciclovir 2.0470.32 1.8270.54 2.0170.14 2.0570.46
Colchicine 2.3570.12 1.2370.24 3.0670.22 1.9770.60
Acrylamide 2.4070.39 1.4570.59 2.6770.32 2.0170.16
Cytochalasin B 2.2870.24 1.5870.69 3.1970.19 2.1970.18
Renal and mammary epithelial cells were infected at a MOI of 0.1. TOFA (250
mg/ml), brefeldin A (5 mg/ml), ganciclovir (10 μg/ml), colchicine (5 mM), acrylamide
(0.4%), cytochalasin B (1 μM) were added 30 or 60 min before infection. At 24 hpi,
virus titers were determined in supernatants (SN) and in cell lysates (IC). Data
represent means7standard deviation (log PFU/ml) of at least three independent
experiments.
n No signiﬁcant difference with any of the tested compounds.
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maturation including expression of viral DNA packaging proteins
and capsid formation and thus prevents the production of viral
progeny whereas TOFA inhibits HCMV replication by blocking fatty
acid biosynthesis (Eggers et al., 1992; Kregler et al., 2009; Munger
et al., 2008). Brefeldin-A, TOFA and the anti-HCMV drug ganciclo-
vir reduced viral replication measured at 7 days post-infection but
did not inﬂuence the detection of infectious virus at 24 hpi.
In addition, HCMV sequestration by epithelial cells was not
inﬂuenced by inhibitors of cytoskeleton remodeling. The cellular
cytoskeleton plays a central role in HCMV infection. The onset of
HCMV replication in ﬁbroblasts requires the presence of intact
vimentin intermediate ﬁlaments (Miller and Hertel, 2009) and the
microtubule network facilitates nuclear targeting of human cyto-
megalovirus capsid (Ogawa-Goto et al., 2003). In addition, micro-
ﬁlament depolymerization is observed very early during HCMV
replication (Arcangeletti et al., 2000). It should be emphasized that
the interpretation of the results obtained with the cytoskeleton
inhibitors is limited by the fact that the experiments did not allow
a formal demonstration of the biological effect of the drugs.
Together, these results indicate that renal and mammary epithelial
cells support the formation of a reservoir of HCMV particles
that is independent of the production of new virions. This
reservoir may have been composed of viral particles that were
unable to enter and infect epithelial cells. Our results showing that
the sequestered virions released in epithelial cell culture super-
natants were as able as the original virus stock to infect epithelial
cells in a secondary culture do not support this possibility and
suggest that cell infection and sequestration are two possible fates
of HCMV virions interacting with renal and mammary epithelial
cells. Of note, the epithelial cells used in this study were not
Fig. 5. Confocal and electron microscopy analyses of HCMV-infected epithelial cells. (A) HEL ﬁbroblasts and human primary renal and mammary epithelial cells were
infected at a MOI of 5 with HCMV strain TB40/E for 24 h before analysis by confocal microscopy. Cell nuclei were stained in permeabilized cells with Toto-3 (red, left panel).
Intranuclear IE1/2 proteins were stained on permeabilized cells (green, middle left panel). Membrane associated gB protein was stained on non-permeabilized cells (green,
middle right and right panels). (B) HCMV-infected cells were ﬁxed at 24 hpi and processed for EM analysis. The image shows the accumulation of mature enveloped virus
particles (MV) in close proximity to the plasma membrane of primary epithelial cells and not ﬁbroblasts (data not shown). Viral like particles are shown in representative
vesicular compartments. Bars, 250 nm. Magniﬁcation: 20,000.
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polarized. Therefore, the interactions between CMV particles and
epithelial cells in vivo cannot be directly translated from our
in vitro system.
Before entering host cells, HCMV interacts with several mem-
brane molecules including HSPGs (Bergstrom et al., 2002;
Compton et al., 1993; Neyts et al., 1992; Song et al., 2001;
Soroceanu et al., 2008). Blocking the interaction of HCMV with
HSPGs by treatment with dextran sulfate or heparinase inhibited
HCMV sequestration by epithelial cells, implicating HSPGs as a
viral receptor responsible for reversible binding. Blocking viral
interaction with HSPGs had a stronger impact on the sequestration
of HCMV by mammary epithelial cells as compared to renal
epithelial cells, suggesting that renal cell HSPGs interact more
strongly with HCMV particles or that other membrane molecules
play a more important role in HCMV binding to renal epithelial
cells. These results indicate that HCMV sequestration by epithelial
cells involves membrane molecules that are also critical to cell
infection and suggest that sequestered viral particles are bound at
the level of the epithelial cell membrane. This notion was
supported by microscopic analyses. The presence of gB protein
was detected by confocal microscopy on non-permeabilized
epithelial cells and a limited number of viral particles were
detected by electron microscopy on the cell surface of epithelial
cells but not on ﬁbroblasts. Although viral particles could not be
demonstrated in association with epithelial cell microvilli, these
structures differentiate renal tubular and mammary epithelial cells
from ﬁbroblasts and could therefore play an important role in
HCMV sequestration (Baer et al., 2006). This possibility was
supported by the observation that sequestered viral particles were
resistant to trypsin and low pH treatment, suggesting that they
were physically protected at the level of the epithelial cell
membrane. On the other hand, the absence of effect of cytocha-
lasin B on viral sequestration may suggest that the sequestration
phenomenon is not dependent on microvilli.
Fig. 6. HCMV sequestration by renal and mammary epithelial cells is inhibited by anti-HCMV antibodies and by IFN-γ. Human primary renal epithelial cells and human
primary mammary epithelial cells were infected at a MOI of 0.1 with HCMV TB40/E. Prior to infection, input virus was incubated with (A) control or immune serum from
three different donors (dilution 1:10) or (B) anti-gB mAb (clone DV1F10G2, 10 mg/ml). (C) Cells were pretreated with IFN-γ (1.33 mg/ml) for 24 h before infection. Data are
means7SD of three independent experiments. ns: Not signiﬁcant, npo0.05 and nnpo0.01 as compared to cultures without inhibitors.
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The phenomenon of sequestration of viral particles by epithe-
lial cells identiﬁed in this study is similar to the one described by
several authors in the context of HIV infection. Epithelial cells from
genital, mammary or renal origin have been shown to bind HIV
particles and transmit infectious virions to CD4 T lymphocytes and
it has been proposed that this process could participate in the
sexual transmission of the virus (Berlier et al., 2005; Dezzutti et al.,
2001; Dorosko and Connor, 2010; Meng et al., 2002; Mikulak et al.,
2009; Wu et al., 2003). Recently, Davey et al. described the
reversible binding of HCMV particles to syncytiotrophoblasts
(Davey et al., 2011). In line with our results, this binding involved
the interaction of viral particles with HSPGs and did not require
viral replication. As demonstrated for HIV, the sequestration of
HCMV particles by epithelial cells of organs involved in transmis-
sion can now be considered as a consistent observation. Whether
the pool of sequestered virus can be inﬂuenced by adaptive
immune responses has an implication for our understanding of
HCMV transmission during primary and recurrent infections and
for the development of vaccines.
Sera from healthy subjects chronically infected with HCMV
efﬁciently decreased the amount of viral particles sequestered by
epithelial cells. Of note, this effect was not observed when
immune sera were added after viral incubation with epithelial
cells, indicating that the viral antigens targeted by antibodies are
either engaged or masked by the sequestration of virions. HCMV
gB is a ligand for HSPGs and is involved in viral entry into
epithelial cells (Tugizov et al., 1996). We observed that a mono-
clonal antibody directed against gB also markedly decreased the
amount of sequestered particles. The antibody response to gB
observed following natural infection or induced by vaccination has
therefore the potential to reduce the viral reservoir formed by
HCMV sequestration at the level of epithelial cells (Axelsson et al.,
2007; Bernstein et al., 2009; Grifﬁths et al., 2011; Jacobson et al.,
2009; Pass, 2009a; Pass et al., 2009b; Wloch et al., 2008; Zhong
and Khanna, 2009). In addition to gB, the envelope glycoproteins
forming the gH/gL/UL128–131A complex play a central role in
epithelial cell infection by HCMV. Further studies should deter-
mine whether this complex is also involved in HCMV sequestra-
tion. A marked reduction of the amount of sequestered HCMV
particles was also induced by IFN-γ when the cytokine was added
to epithelial cell cultures before viral infection. The mechanism
involved in the inhibitory effect of IFN-γ is currently unclear but
could involve the modulation of the expression of viral receptors
by epithelial cells. Together, these results indicate that HCMV
sequestration by renal and mammary epithelial cells is a dynamic
process that can be markedly modulated by neutralizing antibo-
dies and by an anti-viral cytokine.
In conclusion, this study shows that renal and mammary
epithelial cells have the potential to play an important role in
HCMV transmission by supporting productive viral replication and
by sequestering viral particles independently of their replication.
Although primary epithelial cells were studied, in vivo studies are
needed to evaluate the relevance of our observations for HCMV
transmission. The sensitivity of viral sequestration to adaptive
immune effectors suggests that HCMV sequestration may be
modulated by vaccination.
Materials and methods
Cells
Human embryonic lung (HEL) ﬁbroblasts (HEL-299; ATCC CCL-
137) were cultured in minimal essential medium with Earle's salts
(Gibco, Invitrogen Corporation, UK) supplemented with 10% heat-
inactivated FCS. Human primary renal proximal tubular epithelial
cells (CC-2553; REGMs; Lonza, Belgium) were cultured in REGMs
Medium (Lonza) supplemented with the manufacturer's supple-
ment and growth factors kit. Human primary mammary epithelial
cells (CC-2551; MEGM; Lonza) were cultured in MEGMs Medium
(Lonza) supplemented with the manufacturer's supplement and
growth factors kit. Each cell lot was from a single donor. Renal and
mammary epithelial cells were used from passage 2 to passage 12.
Homogeneity of the epithelial cell populations was assessed by the
manufacturer and was conﬁrmed by immunoﬂuorescence in our
laboratory. All experiments were repeated with epithelial cells
obtained from at least two different donors.
Virus
The endothelial-cell-grown HCMV strain TB40/E (kind gift of Z.
Tabi, Cardiff, UK (Moutaftsi et al., 2004)) was used following
propagation in HEL cells. The sequence of the virus used in the
study largely matched the published TB40/E reference sequence
(GenBank EF999921) (data not shown). Infectious supernatants
were harvested when 100% of cells showed a cytopathic effect and
were stored at 80 1C after removal of cell debris by centrifuga-
tion for 10 min at 1800 rpm. Virus titers were determined by a
standard plaque assay. The study involved several virus stocks that
contained a titer of approximately 1105 plaque-forming unit per
milliliter (PFU/ml). All virus stocks were negative for the presence
of mycoplasma.
Reagents
The source of the reagents was as follows: dextran sulfate,
heparinase I, acrylamide, cytochalasin B, tall oil fatty acid (TOFA),
ganciclovir, cycloheximide and sodium citrate buffer (0.09 M,
pH 4.8) (Sigma-Aldrich, Belgium); trypsin/EDTA (Lonza, Belgium);
Brefeldin A (BFA) (BD Biosciences, Belgium) and gamma interferon
(IFN-γ) (R&D Systems, Abington, UK). Sera were obtained from
HCMV-seropositive and seronegative healthy adults. The neutra-
lizing anti-gB mAb DV1F10G2 was kindly provided by Glax-
oSmithKline Vaccines, Rixensart, Belgium. In all experiments
involving the compounds, cell cytotoxicity was assessed by
7-aminoactinomycin (7-AAD) staining and ﬂow cytometry.
HCMV antigen expression assay
Conﬂuent cells grown in 6-well microplates were infected at
the indicated multiplicity of infection (MOI). HCMV-infected and
uninfected cells were ﬁxed in acetone at 4 1C, resuspended in PBS
containing 5% gelatin and incubated at 37 1C in the presence of
mAbs directed against speciﬁc viral antigens: Immediate-Early (IE)
proteins IE72 and IE86 (IgG1; pUL122/123, clone E13; Argène-
Biosoft, Varilhes, France) and Early (E) protein (IgG1; clone 2A2;
Argène-Biosoft, Varilhes, France). Isotype-matched mouse immu-
noglobulins (DAKO) were used as controls. Antibody binding was
revealed using an FITC-conjugated polyclonal rabbit anti-mouse
antibody (DAKO, Belgium). After staining, cells were ﬁxed in PBS
containing 0.5% formaldehyde. Fluorescence was analyzed using a
Cyan ADP LX9 – ﬂuorescence-activated cell sorter and the Summit
4.3 software (DakoCytomation, Belgium).
Virus yield assays
To measure productive infection, conﬂuent cell monolayers cul-
tured in 6-well microplates were incubated with HCMV TB40/E for 2 h
at 37 1C under a 5% CO2 atmosphere before removal of residual virus.
Each well was then thoroughly washed three times with PBS to
remove any loosely and non-adherent virus and cultured for various
periods of time. An uninfected cell control was included at each time
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point. In some experiments, HCMV was incubated prior to infection
with immune serum, non immune serum or with the neutralizing
anti-gB mAb for 1 h at 37 1C. Virus titers were determined in HEL cells
by plaque assay. Virus titers were determined in supernatants after
centrifugation at 1800 rpm 10min to remove cell debris. Cell-
associated virus titers were determined after freezing and thawing
and centrifugation. Virus titers were measured in quadruplicates by
incubating 100microliter of 10-fold serial dilutions of cell supernatants
or cell extracts with HEL cells cultured to conﬂuence in 96-well
microtiter plates. After 7 days, cells were ﬁxed with ethanol and
stained with Giemsa solution. Viral plaque number was determined
by light microscopy examination. The sensitivity of the assay was
1 PFU/100 microliter for each replicate. Viral titers were expressed in
the average log10 PFU/ml of the four replicates.
Quantitative real time-PCR analysis of HCMV pp65 DNA
Conﬂuent cells grown in 6-well microplates were infected at a
MOI of 0.1 and were collected at different times post infection for
DNA puriﬁcation and quantitative RT-PCR analysis of HCMV DNA
Late pp65 expression using the CMV R-gene™ quantiﬁcation
complete kit (Argène, Verniolle, France) and a Lightcycler 2.0
RT-PCR System (Roche Applied System, Belgium).
Confocal microscopy
To detect HCMV gB, cells were seeded onto coverslips in
12-wells microplates, infected with HCMV TB40/E strain for 24 h
and ﬁxed with 4% paraformaldehyde for 10 min at 4 1C. Fixed cells
were then incubated with primary mAb directed against HCMV gB
(anti-gpUL55 IgG1, Genway, Belgium) or an isotype-matched
control mAb (DAKO) for 60 min at room temperature. After
washing, cells were stained with an FITC-conjugated polyclonal
rabbit anti-mouse immunoglobulins (DAKO). Toto-3 (Invitrogen,
Belgium) was used for nuclear staining. Fluorescence was analyzed
using a confocal laser scanning microscope (Zeiss LMS 510).
Electron microscopy
For electron microscopy (EM), HEL cells as well as primary
renal and mammary epithelial cells were grown in 75 cm2 ﬂasks,
infected with HCMV TB40/E at a MOI of 10 PFU/cell and incubated
at 37 1C. After washing, chemical ﬁxation (2.5% glutaraldehyde in
0.1 mol/l PBS buffered with 0.05 M Na cacodylate –pH 7.3 at 4 1C
overnight) was performed at 24 h post-infection (hpi). After 1 h in
1% osmium tetroxide 0.1 mol/l PBS at 4 1C, the sample was
dehydrated in a graded series of alcohol and embedded in epoxy
resin. Ultrathin sections (thickness, 50–60 nm) were cut, stained
with uranyl acetate and lead citrate, and examined at 50 kV using
a Zeiss EM 900 electron microscope. Images were recorded
digitally with a Jenoptik Progress C14 camera system operated
using Image-Pro Express software.
Statistical analysis
Data represent means and standard deviation of at least three
independent experiments and were compared with an unpaired
two-tailed Student t test using the Prism 4.0 statistical software
(GraphPad, San Diego, CA).
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